recent
year
spectr
viral
epidem
even
pandem
becom
realiti
ever
sudden
appear
spread
hiv
alert
gener
public
evil
pathogen
virus
caught
attent
media
throughout
world
sinc
monitor
hiv
outbreak
seen
grow
confront
threat
sar
epidem
recent
tri
prepar
potenti
pandem
avian
influenza
variant
clear
urgent
need
effect
antivir
drug
direct
term
classic
target
like
polymeras
proteas
also
novel
target
novel
mechan
action
new
approach
antivir
therapi
mainli
target
viral
enzym
discuss
follow
paragraph
combin
antihiv
chemotherapi
commonli
refer
highli
activ
antiretrovir
therapi
haart
led
dramat
reduct
mortal
morbid
hivinfect
patient
lee
et
al
thu
far
antihiv
drug
approv
treatment
hiv
infect
despit
avail
approv
antiretrovir
drug
still
need
new
antiretrovir
improv
conveni
reduc
toxic
particular
grow
import
provid
activ
drugresist
hiv
strain
pauwel
emerg
infect
individu
also
transmit
increas
incid
first
lead
compound
nonnucleosid
revers
transcriptas
rt
inhibitor
nnrti
discov
year
ago
pauwel
et
al
merluzzi
et
al
goldman
et
al
de
clercq
et
al
sinc
becom
import
ingredi
drug
combin
scheme
current
use
treatment
human
immunodefici
viru
type
infect
start
hept
tibo
deriv
numer
class
compound
describ
nnrti
four
compound
nevirapin
delavirdin
efavirenz
etravirin
far
approv
clinic
use
sever
other
subject
clinic
trial
balzarini
stellbrink
nnrti
first
approv
nevirapin
even
efavirenz
becam
cornerston
hiv
therapi
potenti
compon
haart
staszewski
et
al
commonli
use
nnrti
drug
efavirenz
addit
nevirapin
shown
effect
prevent
hiv
transmiss
mother
babi
nnrti
proven
benefici
includ
drug
combin
tripl
quadrupl
therapi
prefer
presenc
proteas
inhibitor
nrti
although
nnrti
target
rt
clearli
differ
nucleosid
rt
inhibitor
nrti
highli
select
inhibit
retroviru
moreov
resist
spectrum
nnrti
differ
nrti
rule
nrtiresist
mutant
viru
strain
keep
full
sensit
inhibitori
effect
nnrti
nnrtiresist
mutant
viru
strain
keep
full
sensit
inhibitori
effect
nrti
howev
influenc
nrti
mutat
nnrti
suscept
observ
shulman
et
al
major
nnrti
share
common
conform
properti
structur
featur
allow
fit
asymmetr
hydrophob
pocket
away
catalyt
site
rt
act
noncompetit
inhibitor
kohlstaedt
et
al
howev
nnrti
select
mutant
viru
strain
sever
degre
drug
resist
firstgener
nnrti
nevirapin
delavirdin
efavirenz
easili
lose
inhibitori
potenti
mutant
viru
strain
contain
singl
amino
acid
mutat
rt
resist
develop
primarili
base
emerg
mutat
rt
far
drug
resist
seen
antihiv
drug
class
individu
agent
includ
nnrti
deek
wainberg
bachel
et
al
import
antiretrovir
drug
resist
main
caus
andor
consequ
current
therapi
failur
secondgener
nnrti
usual
requir
two
mutat
rt
signific
loss
antivir
potenc
occur
evid
markedli
longer
period
time
requir
signific
resist
secondgener
nnrti
aris
therefor
compound
offer
consider
promis
futur
drug
initi
clinic
trial
new
nnrti
drug
candid
provid
first
vivo
evid
antivir
potenc
herandez
et
al
gruzdev
et
al
nnrtiexperienc
patient
hammond
et
al
wolf
et
al
gazzard
et
al
exampl
new
gener
nnrti
etravirin
rilpivirin
activ
wild
type
resist
viral
isol
etravirin
approv
us
food
drug
administr
januari
indic
treatment
infect
antiretrovir
treatmentexperienc
adult
patient
evid
viral
replic
strain
resist
nnrti
arv
agent
rilpivirin
show
long
halflif
excel
safeti
profil
use
daili
common
nnrtiresist
mutat
particularli
appear
substanti
impact
activ
etravirin
rilpivirin
moreov
conform
chang
compound
bind
flexibl
rt
hiv
present
higher
genet
barrier
resist
phase
doserang
studi
rilpivirin
found
gener
safe
welltoler
show
sustain
log
declin
hiv
rna
week
maintain
week
given
increas
need
new
nnrti
haart
regim
current
interest
etravirin
successor
drug
rilpivirin
may
becom
next
nnrti
firstlin
therapi
may
conceiv
also
util
peopl
harbour
virus
resist
nevirapin
efavirenz
phase
clinic
studi
rilpivirin
initi
result
eagerli
await
unmet
medic
need
nnrti
higher
barrier
resist
led
increas
interest
next
gener
nnrti
turn
led
sever
drug
current
clinic
develop
three
drug
current
phase
pfizer
idx
idenix
ardea
bioscienc
two
report
phase
activ
ardea
merck
interest
see
drug
develop
strengthen
import
nnrti
hiv
therapi
hiv
integras
one
three
viral
encod
enzym
requir
replic
catalys
integr
viral
dna
host
chromosom
esposito
craigi
asanteappiah
skalka
integras
enzym
encod
togeth
revers
transcriptas
proteas
pol
gene
hiv
gener
virion
matur
proteolyt
process
gagpol
precursor
approxim
integras
molecul
packag
hiv
particl
hiv
integras
consist
three
distinct
domain
ntermin
domain
contain
hhcc
motif
coordin
zinc
atom
requir
viral
cdna
integr
three
highli
conserv
amino
acid
embed
core
domain
form
acid
catalyt
triad
coordin
one
possibl
two
dival
metal
mn
mg
ctermin
domain
residu
respons
unspecif
dna
bind
adopt
overal
fold
chiu
davi
enzym
function
multim
end
three
domain
form
homodim
integr
newli
synthes
viral
dna
host
chromosom
multistep
process
anthoni
van
mael
debys
reli
integr
last
base
pair
end
viral
cdna
besid
fulli
function
integras
see
fig
initi
integras
recogn
longtermin
repeat
ltr
retrotranscrib
viral
dna
perform
endonucleolyt
fig
integr
hiv
dna
host
genom
process
process
end
strand
via
recognit
absolut
conserv
ca
dinucleotid
specif
cleavag
termin
gt
dinucleotid
downstream
therebi
gener
two
recess
hydroxyl
dna
end
serv
nucleophil
follow
strand
transfer
step
process
multimer
preintegr
complex
pic
form
compris
integras
still
bound
viral
cdna
well
viral
revers
transcriptas
matrix
nucleocapsid
vpr
cellular
factor
eg
len
epitheliumderiv
growth
factor
barriertoautointegr
factor
baf
review
see
turlur
et
al
subsequ
hiv
pic
transloc
nucleu
via
intact
nuclear
envelop
karyophil
properti
enabl
hiv
replic
nonprolifer
cell
termin
differenti
macrophag
cleavag
host
dna
viral
hydroxyl
dna
end
ligat
opposit
strand
acceptor
dna
transesterif
reaction
final
ligat
acceptor
dna
last
two
nucleotid
end
viral
cdna
trim
gap
fill
perform
probabl
carri
host
cell
repair
pommier
et
al
sinc
integr
viral
dna
cellular
chromosom
essenti
step
viral
replic
cycl
ensur
stabl
mainten
viral
genom
host
organ
chiu
davi
wiskerchen
mues
repres
attract
target
therapeut
intervent
anthoni
debys
et
al
witvrouw
et
al
kehlenbeck
et
al
accordingli
search
integras
inhibitor
ongo
long
time
recent
met
success
earli
drug
develop
mainli
focuss
vitro
screen
inhibitor
process
howev
show
low
potenc
viral
replic
discoveri
seri
diketo
acid
dka
contain
integras
inhibitor
provid
first
proof
concept
integras
inhibitor
antivir
agent
hazuda
et
al
wai
et
al
dka
deriv
act
specif
strandtransf
inhibitor
trap
select
catalyt
transit
state
process
intermedi
pic
target
catalyt
motif
core
domain
compet
bind
acceptor
dna
chelat
dival
metal
ion
mg
mn
respect
interfac
integras
viral
cdna
complex
grobler
et
al
hazuda
et
al
mode
inhibit
dka
classifi
interfaci
inhibitor
macromolecular
complex
pommier
et
al
expect
novel
mode
action
dkalik
inhibitor
also
shown
effect
clinic
isol
resist
revers
transcriptas
proteas
inhibitor
pi
hazuda
et
al
consequ
triazol
analogu
dka
first
integras
strand
transfer
inhibitor
insti
enter
clinic
trial
develop
stop
phase
iii
billich
subsequ
novel
seri
potent
insti
replac
acid
moieti
isoster
core
show
improv
metabol
stabil
zhuang
et
al
compound
move
clinic
trial
provid
proof
concept
antiretrovir
therapyexperienc
antiretrovir
patient
howev
recent
develop
discontinu
favour
raltegravir
repres
anoth
member
naphthyridin
carboxamid
seri
character
improv
pharmacokinet
profil
embrey
et
al
phase
ii
placebocontrol
studi
advanc
insti
demonstr
unexpectedli
fast
decay
hiv
viral
load
treatmentna
patient
monotherapi
raltegravir
day
result
extens
monophas
decay
dosag
group
ie
mg
twice
daili
median
decreas
log
hiv
rna
copiesml
markowitz
et
al
grinsztejn
et
al
murray
et
al
similarli
combin
therapi
studi
patient
receiv
optim
background
therapi
individu
take
raltegravir
significantli
like
hiv
rna
copiesml
day
day
take
nnrti
efavirenz
plasma
viral
load
lower
initi
secondphas
decay
viremia
patient
receiv
insti
compar
nnrti
addit
raltegravir
demonstr
favour
sideeffect
profil
treatmentna
experienc
patient
review
see
ever
markowitz
octob
raltegravir
approv
us
food
drug
administr
fda
treatment
part
combin
antiretrovir
therapi
treatmentexperienc
patient
reason
appar
superior
antiretrovir
activ
raltegravir
compar
efavirenz
current
understood
sever
hypothes
advanc
first
propos
raltegravir
may
superior
pharmacokinet
properti
allow
penetr
effici
hiv
sanctuari
gutassoci
lymphat
tissu
may
thu
potent
target
major
vivoreservoir
hiv
replic
murray
et
al
second
insti
rti
may
conceiv
inhibit
viru
product
pool
rest
cell
state
preintegr
latenc
murray
et
al
upon
activ
preform
provir
dna
alreadi
locat
nucleu
integr
genom
cell
allow
contribut
viral
load
third
accumul
unintegr
cdna
promot
apoptosi
certain
experiment
condit
vitro
temin
li
et
al
hypothes
insti
could
induc
destruct
longliv
product
infect
cell
macrophag
vivo
accumul
episom
cdna
follow
superinfect
fourth
sedaghat
et
al
use
mathemat
model
studi
decay
dynam
hiv
relat
stage
replic
cycl
inhibit
certain
drug
author
provid
provoc
evid
rapid
hiv
rna
decay
patient
receiv
insticontain
regimen
necessarili
indic
greater
drug
efficaci
may
rather
consequ
fact
drug
act
later
replic
cycl
rti
ongo
clinic
studi
experiment
studi
anim
model
may
shed
light
question
thu
far
unsurpass
potenc
shortterm
viral
load
decay
raltegravircontain
regimen
may
also
import
longterm
perform
patient
haart
sinc
time
suppress
viremia
identifi
import
prognost
indic
louie
et
al
poli
et
al
howev
drug
target
hiv
integras
inhibitor
also
lead
resist
develop
resist
raltegravir
develop
along
two
differ
pathway
posit
hiv
integras
associ
cluster
mutat
expect
far
crossresist
observ
approv
class
hiv
drug
second
clinic
develop
compound
name
elvitegravir
belong
structur
relat
class
integras
inhibitor
satoh
et
al
shimura
et
al
elvitegravir
need
boost
ritonavir
recent
shown
effect
boost
proteas
inhibitor
regimen
cut
viral
load
heavili
pretreat
hivposit
patient
accord
phase
ii
result
drugdrug
interact
studi
alreadi
complet
show
interact
among
observ
mutat
substitut
mainli
contribut
elvitegravir
resist
resist
mutat
confer
reduc
vitrosuscept
inhibitor
includ
raltegravir
suggest
common
mechan
involv
resist
potenti
crossresist
base
current
still
limit
data
set
resist
insti
appear
develop
faster
proteas
inhibitor
quit
fast
nnrti
furthermor
elvitegravir
boost
ritonavir
contrast
raltegravir
raltegravir
given
twice
daili
without
doubt
integras
inhibitor
add
import
new
weapon
antihiv
armamentarium
current
primarili
use
salvag
therapi
regimen
multidrug
resist
patient
may
soon
replac
drug
class
firstlin
haart
helicas
enzym
central
life
natur
doublestrand
dna
mean
polymeras
begin
copi
appropri
region
nucleic
acid
two
strand
unwound
separ
two
strand
function
helicas
fig
indic
signific
famili
enzym
seen
socal
werner
syndrom
helicas
function
requir
suppress
inappropri
recombin
event
defect
caus
genom
instabl
cancer
review
see
cobb
bjergbaek
helicas
divid
two
structur
group
form
ring
surround
nucleic
acid
strand
evolutionari
point
view
helicas
also
group
three
superfamili
gorbalenya
koonin
nonr
helicas
usual
ring
helicas
helicas
exhibit
domain
similar
domain
first
identifi
reca
protein
e
coli
domain
identifi
motor
helicas
power
hydrolysi
ntp
drive
protein
along
nucleic
acid
molecul
ntpbind
site
usual
found
vicin
recalik
domain
herp
simplex
viru
genom
express
two
helicas
replic
cycl
encod
viral
gene
former
found
protein
complex
also
contain
primas
protein
code
report
crute
et
al
kleymann
et
al
boehringerbiomega
bayer
develop
highli
specif
inhibitor
helicaseprimas
complex
hope
clinic
trial
reflect
excel
vitro
activ
vivo
efficaci
alreadi
observ
sever
anim
model
herpesviru
diseas
recent
phase
studi
inhibitor
herp
viru
helicaseprimas
develop
astella
pharma
initi
patient
herp
zoster
genit
herp
japan
usa
see
info
astellascom
sinc
pioneer
work
kleymann
et
al
betz
et
al
baumeist
et
al
crute
et
al
show
compound
identifi
inhibitor
helicaseprimas
enzym
complex
could
allevi
herpesvirusinduc
diseas
anim
model
attent
research
develop
antivir
compound
drawn
toward
virusencod
helicas
particularli
herp
virus
rna
virus
hepat
c
viru
hcv
sar
coronaviru
sarscov
enzym
activ
usual
assay
measur
ntpase
activ
presenc
appropri
nucleic
acid
cosubstr
although
recent
novel
fluorimetr
luminesc
principl
appli
measur
strand
unwind
andor
transloc
protein
along
nucleic
acid
frick
frick
much
literatur
pertain
put
inhibitor
hcv
helicas
recent
discuss
excel
review
publish
frick
point
one
main
problem
helicas
target
antivir
drug
potenti
gener
toxic
relat
highli
conserv
natur
helicas
motor
domain
howev
potenti
inhibitor
direct
toward
alloster
regulatori
site
problem
might
overcom
gener
one
may
expect
nucleosid
analogu
compet
ntp
bind
site
provid
use
inform
role
hcv
helicas
viral
replic
doubt
whether
compound
achiev
success
inhibitor
diseas
process
anoth
mechan
action
explor
competit
nucleic
acid
substrat
maga
et
al
borowski
et
al
describ
tetrabromobenzotriazol
inhibit
unwind
activ
hcv
helicas
albeit
quit
high
concentr
inhibit
ntpase
activ
whether
compound
also
compet
nucleic
acid
substrat
clear
molecul
compound
report
maga
et
al
repres
interest
lead
specif
inhibitor
hcv
enzym
patent
literatur
list
mani
small
molecul
appear
inhibitor
helicas
see
frick
report
develop
one
excit
approach
develop
short
sequenc
rna
bind
specif
hcv
helicas
andor
proteas
activ
found
hepat
c
virusencod
nonstructur
protein
inhibit
helicas
submicromolar
concentr
umehara
et
al
molecul
could
provid
basi
develop
potent
helicas
inhibitor
improv
pharmacotherapeut
properti
helicas
also
focal
point
develop
antivir
chemotherapi
coronaviru
associ
sever
acut
respiratori
syndrom
sar
human
although
sever
experiment
compound
nucleic
acid
bind
activ
show
effect
inhibit
sarscov
helicas
report
report
develop
sinc
time
kesel
remain
seen
whether
sarscov
compound
develop
especi
sinc
new
infect
observ
recent
year
recent
review
state
hcv
helicas
inhibitor
current
develop
expert
believ
difficult
imposs
develop
helicas
inhibitor
hepat
c
support
project
whether
valid
statement
remain
seen
potenti
success
compound
similar
target
herpesvirus
suggest
possibl
develop
inhibitor
hcv
helicas
dismiss
quit
lightli
hcmv
widespread
human
popul
immunocompet
individu
infect
inappar
associ
mild
symptom
howev
hcmv
frequent
transmit
perinat
lead
caus
neurolog
diseas
hear
loss
congenit
infect
newborn
affect
newborn
per
year
usa
alon
arvin
alford
furthermor
follow
first
day
transplant
hcmvinduc
pneumonia
develop
heterolog
bone
marrow
transplant
mortal
rate
left
untreat
de
jong
et
al
approxim
kidney
liver
bone
marrow
heartlung
transplant
recipi
affect
hcmv
hepat
pneumonia
result
decreas
graft
patient
surviv
falaga
et
al
advent
highli
activ
antiretrovir
therapi
haart
hcmv
retin
occur
patient
latestag
aid
jab
use
haart
diminish
impact
hcmv
diseas
significantli
cessat
treatment
patient
virolog
immunolog
failur
potent
antiretrovir
therapi
led
recurr
hcmv
retin
casado
et
al
torriani
et
al
addit
antivir
resist
emerg
aid
patient
hcmv
retin
treat
month
ganciclovir
cidofovir
foscarnet
jab
et
al
b
current
inhibitor
herpesvir
dna
polymeras
licens
prophylaxi
treatment
hcmv
infect
drew
et
al
antihcmv
therapi
elimin
viru
erad
infect
field
current
hcmv
therapi
includ
ganciclovir
gcv
oral
bioavail
prodrug
valganciclovir
foscarnet
pfa
cidofovir
cdv
associ
multipl
side
effect
doselimit
bone
marrow
kidney
toxic
well
emerg
singl
doubl
drug
resist
sarasini
et
al
harada
et
al
antisens
oligonucleotid
fomivirsen
isi
treatment
hcmv
retin
aid
patient
innov
approach
could
appli
intravitr
associ
increas
intraocular
pressur
ocular
inflamm
treat
patient
azad
et
al
today
use
limit
sinc
longer
market
sever
countri
due
commerci
reason
clearli
better
toler
human
cytomegaloviru
hcmv
therapi
novel
mechan
action
need
allow
broader
longer
applic
treat
drugresist
hcmv
aris
therapi
current
approv
agent
process
viral
dna
packag
multifunct
determin
specif
interact
proteindna
proteinprotein
portal
protein
play
import
role
process
portal
larg
macromolecular
complex
found
throughout
herpesvirus
well
doublestrand
dna
bacteriophag
examin
date
black
portal
protein
provid
one
hand
channel
entri
dna
packag
hand
exit
releas
dna
infect
enzym
involv
packag
process
respons
sitespecif
duplex
nick
insert
dna
procapsid
call
terminas
fig
human
cytomegaloviru
hcmv
terminas
compos
two
subunit
larg
small
differ
function
bogner
et
al
bogner
et
al
bogner
larg
subunit
mediat
sequencespecif
dna
bind
atp
hydrolysi
requir
duplex
nick
hwang
bogner
scheffczik
et
al
scholz
et
al
hydrolysi
atp
multipl
function
packag
process
also
involv
format
packag
complex
larg
subunit
stabli
associ
capsid
repres
structur
compon
form
dimer
symmetri
beard
et
al
catalano
sheaffer
et
al
yu
weller
savva
et
al
structur
prerequisit
format
proteindna
complex
requir
packag
procapsid
current
evid
suggest
viral
dna
packag
procapsid
consist
major
capsid
protein
minor
capsid
protein
minor
capsid
proteinbind
protein
smallest
capsid
protein
assembl
protein
proteinas
precursor
protein
gibson
transloc
concaten
viral
dna
procapsid
cleavag
packag
site
understood
recent
studi
herp
simplex
viru
type
mutant
defect
suggest
gene
essenti
involv
viral
dna
cleavag
packag
sinc
cell
infect
mutant
produc
b
capsid
lack
dna
alkobaisi
et
al
bain
et
al
weller
mcnab
et
al
patel
et
al
tengelsen
et
al
yu
et
al
respect
homologu
gene
hcmv
chee
et
al
analog
known
atpdepend
endonucleas
bacteriophag
hcmv
gene
may
encod
endonucleolyt
subunit
put
hcmv
terminas
rao
studi
bogner
et
al
suggest
gene
product
hcmv
open
read
frame
orf
specif
nucleas
activ
well
specif
bind
affin
packag
element
inhibitor
target
viral
terminas
complex
may
offer
attract
altern
present
drug
sinc
mammalian
cell
dna
replic
appear
involv
process
mechan
drug
target
terminaselik
protein
therefor
safe
highli
select
statu
develop
review
follow
paragraph
bdcrb
homologu
tcrb
nucleosid
analogu
activ
hcmv
origin
synthes
townsend
et
al
unlik
current
market
antihcmv
agent
bdcrb
tcrb
inhibit
viral
dna
synthesi
even
concentr
complet
prevent
gener
infecti
viru
instead
exert
antivir
activ
inhibit
hcmv
dna
matur
townsend
et
al
genet
map
experi
show
inhibit
viral
dna
matur
mediat
interact
involv
product
hcmv
orf
kroski
et
al
howev
clinic
develop
pursu
preclin
pharmacokinet
studi
demonstr
bdcrb
tcrb
cleav
vivo
produc
less
activ
cytotox
aglycon
chulay
et
al
sulphonamid
bay
anoth
repres
nonnucleosid
class
inhibitor
hcmv
target
virusspecif
protein
known
requir
cleavag
packag
viral
dna
process
highmolecularweight
viral
dna
monomer
genom
length
reefschlaeg
et
al
larg
panel
laboratori
hcmv
strain
clinic
isol
shown
sever
time
sensit
bay
ganciclovir
ganciclovirresist
well
ganciclovirfoscarnet
ganciclovircidofovir
doubleresist
clinic
isol
suscept
bay
wildtyp
strain
latter
result
suggest
bay
act
mode
action
distinct
dna
polymeras
inhibitor
sequenc
analys
genom
two
bay
hcmv
gener
select
vitro
reveal
sever
amino
acid
exchang
encod
part
put
viral
terminas
minor
structur
compon
virion
capsid
kroski
et
al
data
togeth
dna
cleavag
analysi
indic
alon
interact
repres
molecular
antivir
drug
target
et
al
although
propos
inhibit
hcmv
dna
matur
benzimidazol
ribonucleosid
bdcrb
mediat
gene
product
resist
tcrb
map
two
orf
crossresist
hcmv
sulphonamideresist
strain
bdcrb
reefschlaeg
et
al
expect
requir
accumul
multipl
mutat
gener
resist
phenotyp
may
translat
rel
slow
develop
clinic
hcmv
resist
addit
mechan
distinct
market
drug
offer
possibl
treat
patient
acquir
resist
agent
apart
offer
new
highli
specif
approach
inhibit
herpesvirus
new
mechan
action
could
potenti
also
benefici
immunolog
consequ
treatment
bay
viral
protein
synthesi
continu
due
lack
monomer
genom
length
dna
empti
particl
dens
bodi
form
conceiv
noninfecti
viral
particl
could
aid
establish
antivir
immun
respons
lead
better
control
viru
host
mechan
appear
possibl
case
immunoincompet
host
gain
immun
compet
newborn
transplant
recipi
howev
proof
theoret
benefit
await
clinic
studi
summar
terminas
inhibitor
point
way
toward
switch
strategi
develop
hcmv
inhibitor
aim
achiev
qualiti
differ
establish
dna
polymeras
inhibitor
intervent
viral
dna
matur
arrest
replic
cycl
dna
cleavag
packag
step
lead
accumul
empti
procapsid
unprocess
concatemer
dna
terminas
inhibit
antivir
approach
may
also
consequ
member
herpesviru
group
addit
sinc
similar
dna
matur
process
occur
higher
cell
principl
offer
potenti
high
select
contrast
mani
viral
dna
polymeras
inhibitor
also
interact
cellular
enzym
henc
sever
side
effect
terminas
inhibitor
far
test
clinic
shown
excel
safeti
toler
pharmacokinet
data
singl
oral
dose
healthi
male
subject
nagelschmitz
et
al
reefschlaeg
et
al
viru
matur
assembl
cell
membran
nuclear
membran
long
seen
potenti
target
antivir
compound
viru
matur
releas
conform
insur
stabil
surviv
viral
genom
extracellular
environ
protein
subunit
capsid
nucleocapsid
transport
assembl
point
form
final
particl
around
viral
nucleic
acid
process
occur
orderli
program
manner
capsid
subunit
form
requir
multim
viral
compon
becom
target
cellular
dispos
mechan
dere
colleagu
publish
intrigu
paper
describ
inhibit
hepat
b
viru
hbv
druginduc
deplet
nucleocapsid
dere
et
al
princip
compound
describ
paper
bay
nonnucleosid
heteroaryl
dihydropyrimidin
hap
inhibitor
appear
block
replic
hbv
prevent
format
high
molecular
weight
viral
core
particl
site
dna
replic
aggreg
assembl
hbv
core
protein
subunit
fig
author
conclud
compound
inhibit
particl
assembl
increas
degrad
core
protein
involv
proteasomerel
mechan
hbv
transgen
mice
class
compound
caus
dosedepend
reduct
viral
dna
liver
blood
plasma
oral
applic
furthermor
reduc
amount
core
protein
liver
contrast
antihbv
compound
lamivudin
weber
et
al
hiv
capsid
made
autoassembl
proteasecleav
gag
polyprotein
selfassembl
take
place
appropri
posit
mutat
present
result
drastic
reduc
infect
progeni
viru
recent
three
group
publish
detail
inhibitor
capsid
format
tang
colleagu
describ
chlorin
urea
compound
tang
et
al
welltoler
cell
cultur
inhibit
assembl
capsid
subunit
sticht
colleagu
report
peptid
bind
capsid
protein
alter
dimer
interfac
prevent
selfassembl
way
sticht
et
al
howev
report
develop
compound
perhap
regard
primarili
indic
feasibl
approach
chemotherapi
hiv
infect
anoth
group
describ
betulin
acid
deriv
bevirimat
block
cleavag
gag
polyprotein
viral
proteas
site
zhou
et
al
compound
thu
act
specif
inhibitor
singl
cleavag
site
affect
proteas
cleavag
site
block
cleavag
site
bevirimat
block
viral
matur
infect
tissu
cultur
grant
fasttrack
develop
statu
us
fda
sinc
complet
phase
clinic
studi
five
treatmentexperienc
patient
cohort
unfortun
gag
polymorph
pharmacokinet
factor
appear
affect
respons
bevirimat
howev
effect
blood
level
achiev
target
viru
lack
gag
polymorph
patient
respond
bevirimat
mean
reduct
viral
load
log
unit
panaco
pharmaceut
inc
press
releas
identif
inhibitor
viru
subunit
assembl
object
virologist
sever
year
recent
paper
publish
demonstr
valid
approach
antivir
chemotherapi
hope
inform
provid
compound
describ
provid
foundat
gener
potent
antivir
drug
combat
diseas
caus
hiv
hbv
virus
chapter
describ
spectrum
antivir
activ
discov
beyond
world
nucleosid
analogu
proteas
fusion
inhibitor
compound
mechan
describ
may
one
day
add
significantli
armamentarium
antivir
agent
herp
simplex
hepat
b
human
immunodefici
viru
also
hepat
c
human
cytomegaloviru
